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0019-4832/Copyright © 2015, Cardiological Sgenetic predisposition to CAD.4 Indians have a 2-fold risk of
CAD and a 3-fold risk of diabetes compared to their westerntion of lipid-lowering-treatment (LLT) thresholds for inter-
vention and targets. However, we take exception to the riskIn the last 35 yearswe havewitnessed an impressive 76%e80%
decline in coronary artery disease (CAD) mortality rates in the
United States (US), Finland and other countries.1,2 This dra-
matic decline in CADmortality rates is all themore impressive
as the rates of obesity and diabetesmarkedly increased during
this period.3 The decline is largely due to control of 3 major
established risk factorsdsmoking, high blood pressure, and
elevated cholesterol.1,3 Data review confirms that control of
cholesterol was the eminent factor in reducing risk compared
to all others; and notably, advances in invasive treatments
(stents and coronary bypass surgery) contributed the least.1,3
The escalating epidemic of CAD in India is due to absent or
poor control of the same 3 risk factors, superimposed on a9.
E.A. Enas).
ociety of India. All rightscounterparts when adjusted for various risk factors.4
Indians also develop CAD at a younger age.5,6 These factors
underscore the need for interventions at a lower threshold
and at a younger age for Indians than their Western
counterparts.7,8
We commend Sarat Chandra and colleagues for their
initiative and effort in publishing the Consensus Statement on
the Management of Dyslipidemia in Indian Subjects
(CSMDIS).9 This document fills a deep void and has many
strengths that include an informative discussion on the
burden of cardiovascular disease (CVD) in India, appropriate
strategies for lifestyle intervention, and an excellent elucida-
prediction and stratification in primary prevention (Section 3)
as this would stifle statin therapy for millions of Indians who
are at risk and perpetuate the undertreatment of
dyslipidemia.10,11
Treatment decisions are largely driven by pharmacoeco-
nomics (cost-benefit ratio) in the United Kingdom (UK) where
the health care cost is borne by the government, whereas risk-
benefit ratio drives it in the US.12,13 As Indian patients pay for
their medical expenses one would expect India to be aligned
with the US paradigm. Yet the CSMDIS set 20% CVD risk
within 10 years as the high-risk threshold to qualify for LLT
compared to 10% in the UK and 7.5% in the US.12,13 Despite
access to the same scientific data, recommendations for statin
therapy from India are disparate and restrictive. The use of
statins presently is very low in India, <5% in secondaryreserved.
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that it is even lower in primary prevention.10,11,14
We appreciate the opportunity to present a different
perspective to address the escalating epidemic of CAD in India
6,15 in a 6 question format followed by evidence-based an-
swers on the first 5 questions and our considered opinions on
the last one.1. What is the best measure of atherogenic
cholesterol and what is it's optimal level?
High-density lipoprotein cholesterol (HDLC) is anti-
atherogenic and the remainder of cholesterol (total choles-
terol minus HDLC) is atherogenic and termed non-high den-
sity lipoprotein cholesterol (NHDLC).16 NHDLC includes all
Apo B containing lipoproteinsdlow-density lipoprotein
cholesterol (LDLC), very LDLC (VLDLC), intermediate density
lipoprotein cholesterol (IDLC), lipoprotein (a) and remnant
cholesterol. NHDLC is both a necessary and sufficient risk
factor for atherosclerosisdthe underlying pathophysiological
process in CVD.17 Necessary risk factor, because atheroscle-
rosis does not develop in the absence of some elevation in
NHDLC. Sufficient risk factor, because atherosclerosis de-
velopswhenNHDLC concentration ismarkedly elevated, even
in children as young as 6 years of age, without other risk
factors.17
NHDLC, appropriately emphasized in CSMDIS, is being
increasingly recognized as a better predictor of CVD risk than
LDLC, and has the practical advantage of not requiring a
fasting measurement.16 For any given level of total choles-
terol, Indians tend to have greater elevation in NHDLC by
virtue of high triglycerides and low HDLC common in this
population.18,19
The optimal NHDLC is defined as <130 mg/dL which cor-
responds to a LDLC <100mg/dL and total cholesterol <150mg/
dL16. Evidence gathered in the past decade also supports a
NHDLC of goal of <130 mg/dL for Indians with low, medium
and high risks (Table 1).16,20e25 In people with very high risk
(established CVD, diabetes, and lifetime risk45%) the NHDLC
goal is < 100 mg/dL.16,26 More stringent goals (NHDLC <75 mg/
dL and LDLC< 50 mg/dL) have emanated from 2013 American
College of Cardiology (ACC)/American Heart Association
(AHA) guidelines and other studies.12,23e26
The best measure of atherogenic cholesterol is NHDLC and
the optimal level is < 130 mg/dL for Indians.2. How effective and safe is statin therapy?
Statins offer the most effective treatment to lower NHDLC by
lowering both LDLC and triglycerides >50% (1:1 ratio).18,27
More than 200 million people worldwide have taken statins
since it was first introduced in 1987 and 170,000 were studied
inwell-designed randomized clinical trials; its excellent safety
record surpass all other lipid-lowering medications.12,27e30
A recent discovery is that statin is the most effective
medication to lower CVD risk.12,27e30 Hence its use is not
limited to patients with dyslipidemia or CAD but extends to all
patients with elevated CVD risk.12,27e30 Because of theimpressive effect of statinmedications in reducing CVD risk, a
paradigm shift in statin therapy has occurred in that it's use is
no longer restricted to those with high LDLC or NHDLC.12,27e30
The broader use of statins in CVD risk reduction is analogous
to the use of ACE inhibitors for cardiac and renal protection in
the absence of hypertension.18 The absolute CVD benefits of
statin therapy are proportional to the intensity of therapy, the
age of initiation of such therapy and the baseline risk of the
individual (but not necessarily the baseline cholesterol
level).18 Most importantly, the benefit of statin therapy in
primary prevention far outweighs the risk even in people with
5% CVD risk within 10 years.29
A meta-analysis of statin trials has demonstrated that
every 80 mg/dL decrease in LDLC safely reduces the 5-year
incidence of major CVD events by 42% and total mortality by
24%.31 In primary prevention in every one million very high-
risk persons (60% risk of CVD within 10 years), high-
intensity statin therapy (that lowers LDLC by 98 mg/dL) pre-
vents 9200 deaths and 28,400 CVD events.29 Most importantly
among those with <10% CVD risk within 10 years, high-
intensity statin therapy can prevent 600 deaths and 1200 to
2400 CVD events.29
Many physicians and patients underestimate the absolute
benefits and overestimate the absolute risks of statin ther-
apy.18 The absolute number of CVD events prevented (as dis-
cussed above) are 100 times greater than the absolute number
of adverse events producedean average excess of 3 deaths, 20
rhabdomyolysis, 100 myopathy, and 100 hemorrhagic stroke,
per one million persons-years of statin therapy.12,18 Contrary
to a popular misconception, statins do not cause dementia
and may actually decrease its risk by 29%32. The increased
CVD risk resulting from statin-related new-onset diabetes is
60 times smaller than CVD prevented from statin therapy.12
The excess risk of diabetes is 0.1% per year for low to mod-
erate intensity and 0.3% per year for high intensity statin
therapy. The risk of diabetes is also limited to those who are
obese, sedentary and already on the path to diabetes.12,18 The
evidence suggests that statin therapy might shorten the time
to diabetes by a few weeks or months but not years.18 Statins
may affect diabetes risk in the complex interplay between
lipids, glycemia, LDL receptor function and obesity.33 The
safety and efficacy of statins is much greater than other forms
of LLT.12,18
Statin therapy is effective and safe; the benefits far
outweigh safety concerns.3. What is the minimum age to measure
lipid levels in Indians?
The range of recommendations available must be viewed in
the context of the populations studied whether based on cost-
benefit or risk-benefit analysis, and in conjunction with ad-
vances in scientific information on the topic. European
guidelines recommend measuring lipid levels at age 40,
whereas the 2013 AHA/ACC guidelines recommend lipid
measurements at 20 years of age.12 The National Institute of
Health (NIH) of US sponsored major report “Integrated
Guidelines for Cardiovascular Health and Risk Reduction in
Children and Adolescents” (202 pages and 841 references),
Table 1 e Recommendations for lifetime risk estimation, stratification, and management of dyslipidemia among Indians.
A 4 Risk factors categorized as minor, moderate, and major
Risk factor category Smoking Diabetes Systolic blood pressure Total cholesterol
Minor N/A N/A 120e139 mm Hg 180e199 mg/dL
Moderate N/A N/A 140e159 mm Hg 200e239 mg/dL
Major þþþ þþþ 160 mm Hg 240 mg/dL
B Lifetime CVD risk estimation men and women in urban and rural India
Men Women
White Urban Indian Rural Indian White Urban Indian Rural Indian
No risk factor 5% 9% 5% 8% 12% 6%
1 minor 25% 45% 25% 10% 15% 8%
1moderate 38% 69% 38% 22% 34% 18%
1 major 45% 81% 45% 25% 39% 20%
2 Major 60% 109% 60% 45% 64% 36%
Calibration factor 1.0 1.81 1.0 1.0 1.54 0.8
C Lifetime CVD risk stratification to match the severity of risk with intensity of preventive interventions
Treatment goal (mg/dL)
Lifetime risk stratification Intensity of intervention Lifestyle therapya Statin therapyb NHDLC LDLC
Low <15% Low þ Usually no <130 <100
Medium 15e29% Moderate þþ Optional <130 <100
High 30e44% Moderately high þþþ Strongly consider <130 <100
Very high 45% High þþþþ Strongly Indicated <100 <70c
LDLC ¼ low-density lipoprotein cholesterol; N/A ¼ not applicable; NHDLC ¼ non-high density lipoprotein cholesterol.
a Includes not smoking, regular exercise, consuming a healthy diet, and maintaining ideal body weight and waist circumference.
b Unless contraindicated or not tolerated.
c Optional goal is NHDLC <75 mg/dL and LDLC <50 mg/dL.16,20e26
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between the ages of 9 and 11 and again between the ages of 15
and 17 years.34
The CSMDIS recommendation to delay lipid measurement
to 30 years of age is questionable for a population with the
highest risk of premature CAD.5 This delay potentially allows
unfettered plaque buildup for 3 decades in Indian residents,
where more Indians <30 years of age die from CAD (420,000
per year) than people of all ages in the US (375,000 per year).2,6
The landmark Framingham Offspring Study has demon-
strated CAD risk is higher in those exposed to hyperlipidemia
for longer periods.35 For example, CAD risk was 2-fold among
those exposed for 10 years, increasing 4-fold among those
with 2 decades of exposure to moderate hyperlipidemia
(NHDLC 160 mg/dL or LDLC 130 mg/dL).35
Meta-analysis of statin trials inmiddle-aged adults showed
reduction of CVD of 21% for every 39 mg/dL reduction in
LDLC31; notably the risk reduction was nearly 3 times higher
with statin therapy initiated at age 35 (54%) compared to statin
begun at age 65 (20%).36,37 Mendelian randomization studies
have demonstrated that a 38 mg/dL lifetime difference in
LDLC (100 mg/dL vs 138 mg/dL) is associated with 88% lower
rates of CAD.37e39 Genetic and epidemiological studies
confirm that CVD risk reduction with lifelong low LDLC levels
is 3e5 times greater than lowering LDLC in middle-aged
adults.37e39 The fact that CVD risk reduction with lifelong
low LDLC levels is far better, provides the rationale for early
initiation of Maximal Lifestyle Therapy (MLT), beginning in
childhood.37e39 American guidelines recommend statin ther-
apy for high-risk children as young as 10 years of age and is
indicated when LDLC is  190 mg/dL without other risk fac-
tors.34 Among children with LDLC 130e189 mg/dL, statin
therapy is indicated in the presence of other risk factors.34
Several statins are FDA approved for pediatric use.We recommend measurement of lipid levels at age 20 for
all Indians and at age 10 for those with a family history of
dyslipidemia or CVD.4. What are the limitations of 10-year risk
estimation and a high-risk threshold of 20%?
In primary prevention, the fundamental tenet is to match the
intensity of preventive interventions with the severity of CVD
risk.12,13,40 The severity of risk is typically evaluated by using
various risk prediction equations that traditionally assess the
risk of developing CVDwithin 10 years.41 High-risk thresholds
vary between countries, depending primarily on whether the
risk-benefit ratio or cost-benefit ratio is factored.12,13 In the
UK, which follows the cost-benefit ratio, adoption of 40% CVD
risk within 10 years was considered economical; although this
would deny statin therapy to 99% of the population the op-
portunity to stem CAD.13 As the costs of statins have fallen,
the high-risk threshold for statin therapy has also fallen pre-
cipitously in the UK from 40% in 1990 to 20% in 2004, and to
10% in 2014, with a corresponding increase statin-eligible
population from 1% in 1990 to 19% in 2004 and half the pop-
ulation in 2014.13
The ACC/AHA guidelines state a high-risk threshold of
7.5% (within 10 years) with an option for statin therapy at
threshold of 5% after consideration of secondary factors.12
The difference in the high-risk threshold for statin therapy
between the US and UK is partly due to the difference in the
Risk Prediction Equations used, which in turn have different
CVD endpoints. The Pooled Cohort Equations (PCE) used in the
US includes only hard CVD end points (fatal and nonfatal CAD,
myocardial infarction, and stroke) whereas QRISK2 used in
the UK includes hard CVD end points plus soft end points
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the 10% CVD risk by QRISK 2 and 7.5% by PCE are generally
comparable. The use of statins was liberalized in the US in
2013 and in the UK in 2014, resulting in wider eligibility for
primary preventionwith statin therapy. AmongUS adults (>40
years of age), 26% are on statins including 63% of those with
diabetes and 54% of those with elevated cholesterol.14
CSMDIS has restricted the wider use of statins in India
when it set a 20% of CVD risk within 10 years as the high risk
threshold for statin therapy in primary prevention.9 The
threshold is too high and indefensible based on accumulated
evidence.12,13,16,26,40 To illustrate this comment in clinical
context, let us consider the statin eligibility for an Indianmale
(case 1) and a female (case 2), both having the following risk
profile: Age 30, heavy smoker, family history of premature
CAD, obesity (height 165 cm weight 70 Kg, BMI 26), systolic
blood pressure (SBP) 160 mmHg without treatment, total
cholesterol 280 mg/dL, and HDL 40 mg/dL). Would you not
start these patients on statin therapy? QRISK2 risk calculator
gave a 10-yr CVD risk of 9% for case 1 and 6% for case 2d far
below the 20% high-risk threshold recommended by CSMDIS.
Case 1 would have to wait until age 40 and case 2 until age 49
to reach the 20% risk threshold for statin therapy (recom-
mended by CSMDIS).9 Nonetheless, both would have qualified
for statin therapy if the ACC/AHA optional high-risk threshold
of 5% were applied.12
A major problem with the 10-year CVD risk calculation is
that it is heavily influenced by age.12 As an example, 10-year
CVD risk for a 70 year-old male without other risk factors
(cholesterol 170 mg/dL, HDLC 50 mg/dL, SBP 110 mmHg
without treatment, no smoking and no diabetes) is 13%,12
whereas for a 30-yr old with multiple risk factors as
described in cases 1 and 2 have a risk of 9% and 6%
respectively. This underestimation of CVD risk at younger
ages may not be a problem in developed countries such as
the US, where 81% of CVD deaths occur in people 65 years
of age and only 1% of deaths in whites and 4% of deaths in
blacks occur in those <45 years.2,6,43 In sharp contrast, un-
derestimation of risk is a major problem in India, where 42%
of all CAD deaths occur in people <45 years of age (1.2
million annually).6
Two thought provoking reports from India and Denmark
highlight the importance of using appropriate risk thresholds
when ACC/AHA/PCE is used to identify statin eligible patients
among those presenting with the first acute myocardial
infarction (AMI).44,45 Among Indian patients (median age 59)
only 30% would have qualified for statin therapy when
CSMDIS criteria (20% CVD risk within 10 years) was applied.44
However, among Danish patients <60 years of age, 65% ofmen
and 12% of women would have qualified for statin therapy
when ACC/AHA criteria (7.5% CVD risk within 10 years) was
applied.45 Further, 70% of men and 30% of women would have
qualified for statin therapy when the optional criteria (5%
CVD risk within 10 years) was applied.45These data under-
score the importance of selecting not only the right risk pre-
diction equation but also defining the appropriate threshold
for statin therapy for Indians.
A 10-year CVD risk of 5% is a more appropriate threshold
for Indians for statin therapy than 20%. However, because of
the many variables that potentially deprive statin therapy tomillions of patients who would benefit from it and because of
the need for cumbersome estimation tools, it is time to put the
10-year CVD risk estimation tool to rest. Instead consider a
better alternative (discussed below).5. What are the advantages of lifetime risk
estimation and stratification of CAD in Indians?
The aim of preventive intervention in CVD should not be
limited to 10 years but should be to reduce the morbidity and
mortality due to CVD for a life time thus aiding healthy aging.
A noteworthy publication from India highlighted the impor-
tance of estimating lifetime risk among Indians with low
short-term risk.46 In this study, 76% (approximately one in 2
men and 3 in 4 women) had low-risk of CAD (using 10% CVD
risk within 10 years as the high-risk threshold).39 However,
half of those with low short-term risk had a high lifetime risk
qualifying for intensive interventions. As a result, the pro-
portion of high-risk individuals increased by 150% (from 24%
using 10-yr risk estimates to 61% when lifetime risk was
estimated).46
The Global Recommendations for the Management of
Dyslipidemia by the International Atherosclerosis Society
(IAS), published in 2013 estimates only lifetime risk (defined as
risk to age 80) effectively eliminating the limitations of a 10-
year risk estimation.16 The full IAS document can be down-
loaded from the IAS website: http://www.athero.org/
download/IASPPGuidelines_FullReport_20131011.pdf.
The IAS lifetime risk estimation and stratification has
several advantages over other tools (Tables 1 and 2).16,20e26
Most importantly, the IAS algorithm considers only 4
major risk factors and 4 levels of lifetime risk. Major risk
factors are cholesterol >240 mg/dL, SBP >160 mmHg,
smoking, and diabetes. Cholesterol 200e239 mg/dL and SBP
140e159 are moderate risk factors; cholesterol 170e199 mg/
dL and SBP 120e139 mm Hg are minor risk factors. Levels of
lifetime risk are: very high 45%, high 30e44%, moderate15
-29%, and low <15%. This stratification forms the basis for
recommending LLT: indicated for those at very high risk, to
be strongly considered for those at high risk, optional for
those with moderate risk and not indicated for low risk
individuals.16
To view risk stratification in the clinical context of the 2
illustrative cases mentioned earlier (under 4), and now reex-
amining them using the IAS tool, case 1 would have a lifetime
risk of 109% and case 2, 64%, far above the 45% high-risk
threshold (thereby qualifying for statin therapy).16 This IAS
lifetime risk estimation took less than a minute without the
aid of a computer or internet access.
All CVD risk scores have different accuracy in different
populations, tending to over predict CVD risk in low-risk
populations (such as Chinese, Japanese, and Southern Euro-
peans) and under predict the risk in high-risk populations
(such as Indians and Russians).2,22 A multitude of protective
factors and harmful risk factors contribute to differences in
baseline population risk. Several studies have shown 150%e
220% higher CVD mortality among South Asians compared to
whites in the UK, despite equal access to health care (and
after adjustment for all major risk factors including
Table 2 e Advantages of International Atherosclerosis Society lifetime risk estimation and risk stratification for Indians.
1 Assessment of lifetime risk Lifetime risk provides more accurate estimation of CVD risk among Indiansda population with the
highest rates of premature coronary artery disease (CAD). Age, the principal driver of
underestimation of premature CVD risk is eliminated from the risk estimation algorithm
2 Simplicity Simple algorithm requiring no internet access or calculators
3 4 risk categories Very high (45%), high (30e44%), moderate (15e29%), and low (< 15%)
4 4 major risk factors only Diabetes, smoking, cholesterol 240 mg/dL and SBP 160 mm Hg
5 2 moderate risk factors only Cholesterol 200e239 mg/dL and SBP 140e159 mm Hg
6 2 minor risk factors only Cholesterol 180e199 mg/dL and SBP 120e139 mm Hg
7 Country/Ethnic/gender specific
calibration coefficients reflecting
the baseline risk
China 0.36, Italy 0.37, France 0.41, Germany 0.43, UK and Ireland 0.74, US 1.0, rural Indian men 1.0,
rural Indian women 0.8, urban Indian men 1.81, urban Indian women 1.54.
8 Absolute lifetime risk estimation Multiply the estimated lifetime risk with the recalibration coefficient; this allows to compensate for
significant over or underestimation of risk in certain populations.
9 Definition of atherogenic
cholesterol
Atherogenic cholesterol is defined as NHDLC and it is calculated by subtracting HDLC from
cholesterol level.
10 Definition of and its optimal level The optimum level of NHDLC is <130 mg/dL, which corresponds to LDLC <100 mg/dL and total
cholesterol <150 mg/dL.
11 Rationale for the use of NHDLC NHDLC is a better predictor of CVD risk than LDLC, although LDLC has been the traditional target of
lipid-lowering therapy for decades. NHDLC has the additional advantage of not requiring fasting or
additional expense for estimation.
12 Reduction in lifetime CVD risk
with treatment of risk factors
Unlike 10-year risk estimationwhich is fixed, lifetime CVD risk estimation is dynamic; lifetime CVD
risk, therefore, risk can be substantially reduced by treatment of risk factors (such as treatment of
high blood pressure, high cholesterol or smoking cessation).
CAD ¼ coronary artery disease; CVD ¼ cardiovascular disease; LDLC ¼ low-density-lipoprotein cholesterol; NHDLC ¼ non-high-density-lipo-
protein cholesterol; SBP ¼ systolic blood pressure; Refs. 16,20e23.
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delineated specific calibration coefficients to compensate for
the underestimation and overestimation CVD risk among
different populations in the world. This coefficients vary by
ethnicity and range from as high as 1.8 for urban Indian men
and 1.54 for urban Indian women to 1.0 for rural Indian men
and 0.8 for rural Indian woman and as low as 0.5 for Japanese
Americans and 0.36 for Chinese.20e22 The estimated CVD risk
is multiplied by these calibration coefficients to arrive at the
true absolute CVD risk in a given population. The high cali-
bration coefficient for urban Indians appears related to a
higher prevalence of lipoprotein(a)50 and metabolic syn-
drome,51 combined with unhealthy diet (low intake of fruits,
vegetables, whole grains, and fish, and high intake of full-fat
dairy products and fried food, a surrogate for trans fats,
etc.).52 The high prevalence of protective factors among
Chinese, Japanese and Italians, and Native Americans
(American Indians) possibly account for their low calibration
coefficients.4
Based on the preceding discussion, it follows that when the
IAS algorithm is used compared to 10-year risk stratification,
far more Indians would fall in the stratum for statin therapy
even when the LDLC level is not significantly elevated. For
example, an Indian male with 1 and Indian female with 2
major risk factors would have a lifetime CVD risk of 81% and
64% respectively and therefore require high-intensity statin
therapy; this is because of their CVD risk exceeds the high risk
threshold of 45%.16
Another advantage of lifetime risk calculation is that it is
not a fixed entity and the risk would decrease with appro-
priate therapy.16 For example, control of blood pressure or
cessation of tobacco use can downgrade the lifetime risk to a
lower category and reduce the dose of statin or possibly even
obviate the need for it, provided the NHDLC level is in theoptimal range. This is in sharp contrast to 10-yr risk esti-
mation based on a single measurement that does not pro-
vide adjustments for changes in risk due to interventions
such as smoking cessation or statin therapy started after
enrollment.
The IAS risk estimation and stratification algorithmmay be
further refined, at a later date, by incorporating other factors
such as chronic kidney disease, microalbuminuria, family
history of premature CVD, ankle-brachial index <0.9, Coro-
nary Artery Calcium Score (CACS) > 300 Agaston units, and
lipoprotein (a) 50 mg/dL (>125 nanomol/L)26.
Despite its simplicity and ease of use, some physiciansmay
be unwilling to try the IAS and other risk prediction algo-
rithms. Therefore, physicians may be offered the option to
treat high cholesterol just the same way as they treat hyper-
tension, based exclusively on the cholesterol levels. It seems
reasonable to recommend statin therapy to individuals with
cholesterol 180 mg/dL or NHDLC 160 mg/dL.16,53 This op-
tion is particularly important in India, where many busy
practitioners, including cardiologists see asmany as 200 to 300
patients a day.53 This option would reduce the number of
patients requiring risks scoring. However, this would leave
behind a large number of patients withmultiple non-lipid risk
factors that magnify the CVD risk and therefore should not be
the preferred option.
The IAS lifetime risk estimation and stratification algo-
rithm is the best method to identify and treat Indians at high-
risk for CAD at a younger age. The IAS algorithm with the
calibration factors also lowers the bar for initiating statin
therapy for millions of Indians, who would greatly benefit
from it. Besides it is also easy to use and is flexible as therapy
can be modified as risk factors change. For these reasons we
endorse statin therapy on the basis of lifetime risk estimation
and stratification.
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use of statins for primary prevention of CVD in
India?
Besides the issue of underestimating risk factors, a major
impediment to combating CVD in India is the underuse of
indicated medications, especially statins that reduce CVD
morbidity and mortality.10,11,54 In a broader context, the issue
of under treatment is not confined to dyslipidemia but also to
chronic diseases such as diabetes and hypertension.10,11,54
The concept of lifelong treatment is not understood by many
patients and unfortunately not fully understood or embraced
by some physicians.
Some practitioners including cardiologists seem eager to
reduce or stop life-saving medications as soon as the blood
pressure or cholesterol level has barely reached the goal.
Some also practice the provision of offering “drug holidays”
to patients. Repeated reinforcements by educational pro-
grams may help change the mind set of some practitioners
to remember the chronic disease management dictum
“treatment is lifelong, if not, life may not be long.” Since they
receive little information from doctors, pharmacists or
pharmaceutical companies, many patients are totally in the
dark as to “what medications are prescribed for what con-
ditions” and fail to differentiate between life-saving medi-
cations, vitamin supplements and other non-essential
medications.
Primary care physicians (general practitioners) write two-
thirds of statin prescriptions in the US and Europe but not so
in India. There is no compelling reason why Indian general
practitioners should not manage dyslipidemia in their pa-
tients. In primary prevention, but not in secondary preven-
tion, statin therapy is reserved for those who fail to achieve or
maintain the risk adjusted NHDL levels withmaximal lifestyle
therapy, which should be started before and continued during
statin therapy. It is important to continue statin therapy life-
long unless competing diseases have reduced the quality and
quantity of life.
In the US, most prescriptions for high blood pressure and
high cholesterol are written for three months at a time (and
sometimes for 1 month with 3 refills). Bottles containing 100
tablets are the norm rather than the exception. In contrast,
most patients in India buy “medication strips” that usually
last one or 2 weeks. Many patients wait a week or 2 to buy the
next strip. Cultural beliefs and socioeconomic status com-
pound thewoes. Patients consume a third or less of prescribed
dosage contributing to poor control of hyperlipidemia. We are
not unmindful of the financial, educational and cultural dif-
ficulties that patients in India face in understanding and
dealing with chronic diseases and accepting the need for life
long medications. While recognizing that there are no easy
solutions, we encourage physicians to take leadership roles in
educating patients and families directly and through print,
visual and social media. Cardiologists, rightly so, should take
the lead in the domains of CAD, its risk factors and manage-
ment of dyslipidemia by teaching their primary care col-
leagues, medical students and physicians in training.
Strategies must be developed to enable Indian general
practitioners champion the provision of statin therapy inprimary prevention of CVD. Every effort should be made to
make treatment of dyslipidemia as easy as the treatment of
hypertension and diabetes by educating physicians and
public.
The 2013 ACC/AHA cholesterol guidelines sparked efforts
to promote statin use in many high-risk patients who were
hitherto undertreated in the US.12,55 We hope that this com-
mentary will aid Indian physicians navigate through the oc-
casionally differing recommendations in the American,
European and Indian guidelines. While we agree on most of
the CSMDIS guidelines we urge the guideline writers to make
changes in Section 3 that dealswith primary prevention giving
due consideration to our perspective. We hope the revised
guidelines would then foster a public health strategy that fo-
cuses on sustained reduction of NHLDLC throughout the
lifespan that would reduce the excess burden of CAD among
Indians. It is time to expand the widely accepted LDLC and NHDLC
dictum from “the lower the better” to “lower and earlier the
better”.18Conflicts of interest
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